silodosin / Generic mfg. - LARVOL DELTA

Differential Risks of Dementia, Depression, and Injury Among Common α-Blockers, with Tamsulosin as the Reference Drug: A Real-World Cohort Study in Men with Lower Urinary Tract Symptoms. (PubMed, J Clin Med) - "Patients were grouped by α-blocker type-tamsulosin, doxazosin, terazosin, alfuzosin, silodosin, or prazosin-and matched 1:1 using propensity scores to adjust for demographic, clinical, and psychosocial variables. Given its favorable profile, alfuzosin may be the preferred agent in patients at elevated risk of cognitive or psychiatric disorders. These findings highlight the need for individualized α-blocker selection and long-term pharmacovigilance in BPH management."

Journal • Real-world evidence • Alzheimer's Disease • Benign Prostatic Hyperplasia • CNS Disorders • Dementia • Depression • Mental Retardation • Oncology • Psychiatry

Silodosin in treating men With BPH-associated lower urinary tract Symptoms: A systematic review and network meta-analysis. (PubMed, Int J Surg) - "Silodosin is highly effective for BPH-LUTS, particularly for voiding symptoms, but carries a elevated risk of ejaculatory dysfunction. Combination with tadalafil may enhance urinary flow. Clinicians should weigh efficacy against adverse events; further trials are needed to confirm long-term benefits."

Journal • Retrospective data • Benign Prostatic Hyperplasia

Comparative evaluation of safety and efficacy of dapoxetine, silodosin, and citalopram in the management of premature ejaculation: a randomized clinical trial. (PubMed, BMC Urol) - P4 | "In this direct head-to-head comparison of active treatments for lifelong PE, daily citalopram (20 mg) demonstrated superior efficacy in prolonging IELT and improving psychosocial outcomes compared to daily or on-demand dapoxetine and silodosin. The findings suggest that citalopram is a highly effective first-line option, while the dose-dependent efficacy of dapoxetine and the distinct side-effect profile of silodosin provide alternative considerations for personalized treatment strategies."

Clinical • Journal • Sexual Disorders

Comparison of Preoperative Alpha-Blocker Therapy Versus Placebo Before Ureterorenoscopy and Lithotripsy for Distal Ureteral Stones. (PubMed, Cureus) - "In Group A, URS and lithotripsy were performed after two weeks of alpha-blocker therapy (silodosin 8 mg once daily), while in Group B, URS and lithotripsy were performed after two weeks without alpha-blocker therapy (placebo group)...The use of alpha-blockers is recommended to enhance procedural outcomes and minimize the risk of complications during URS and lithotripsy. Further studies with larger sample sizes and longer follow-up periods are warranted to confirm these findings."

Journal • Benign Prostatic Hyperplasia • Nephrology • Renal Calculi • Transplantation • Urology

Management of acute urinary retention in men with benign prostatic hyperplasia: Literature review and guidelines from the French Urological Association Male LUTS Panel (CTMH). (PubMed, Fr J Urol) - "These CTMH guidelines provide evidence-based recommendations for AUR management, emphasizing alpha-blocker therapy before trial without catheter and considering patient-specific factors when selecting drainage methods. Further research is needed to optimize surgical timing and technique selection."

Clinical guideline • Journal • Review • Anesthesia • Benign Prostatic Hyperplasia

Efficacy of daily silodosin 8 mg as a potential reversible male contraceptive: A prospective placebo controlled study. (PubMed, Int Urol Nephrol) - "Silodosin 8 mg yields a better sperm suppression results as on-demand male contraception after 3 months of continuous daily oral intake when compared to placebo, associated with pregnancy rate of 4% and higher but tolerable side effects."

Journal

E3 ligase CHIP restoration facilitates the effect of α1-adrenoceptor blockage on alleviating lipopolysaccharide-caused cardiac fibrosis via downregulating TGF-BR1 expression and Smad2/3 activation. (PubMed, Mol Biomed) - "Furthermore, we innovatively revealed that α1A-AR is the dominant α1-AR subtype in CFs, and its specific antagonist, silodosin, eliminated NE-mediated CFs differentiation and LPS-induced myocardial fibrosis, which was consistent with the action of prazosin. These findings demonstrate the protective effect of α1-AR blockage against LPS-mediated myocardial fibrosis, which is achieved by directly inhibiting the PKC-p38-Smad2/3 signaling pathway and promoting TGF-BR1 downregulation through restoring CHIP expression."

Journal • Fibrosis • Immunology • Infectious Disease • Septic Shock • Targeted Protein Degradation • JUN • SMAD2 • ST13 • TGFB1

Comparing Tamsulosin vs. Silodosin prior to Ureteroscopy: A Network Meta-Analysis of Randomized Controlled Trials. (PubMed, World J Urol) - "Silodosin and Tamsulosin are both viable options pre-URS, with Silodosin potentially yielding shorter operative time, less ureteral dilatation required and higher SAR. However, these differences are non-significant and stem from indirect estimates. Therefore, randomized head-to-head comparison trials are warranted."

Clinical • Journal • Retrospective data • Review • Renal Calculi • Urolithiasis

Induction of apoptosis and growth inhibition by silodosin and abiraterone acetate in PC-3 human prostate cancer cells. (PubMed, Investig Clin Urol) - "Silodosin exhibits potent effects in reducing cell viability and promoting apoptosis in androgen-insensitive prostate cancer cells, comparable to AA. When combined, both agents demonstrate synergistic effects with reduced dosing requirements. These findings support further investigation of silodosin as a potential therapeutic in mCRPC."

Journal • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • ANXA5

The Discovery of α-Adrenoceptor Antagonists as a Potential New Treatment Option for Uveal Melanoma. (PubMed, Biomolecules) - "Drug screening with UM spheroids revealed that prazosin and doxazosin dose-dependently reduced viability, whereas terazosin, alfuzosin, silodosin, tamsulosin, and phenoxybenzamine were found to be inefficient. This suggests a tumor-preventive effect through the blockade of α1A-AR. The present study highlights the responses of UM spheroids to α-AR antagonists and demonstrates that prazosin, doxazosin, or RS17053 may be a treatment option for preventing UM tumor recurrence or metastasis."

Journal • Eye Cancer • Hepatocellular Cancer • Melanoma • Ocular Melanoma • Oncology • Solid Tumor • Uveal Melanoma • AR

Silodosin as a Novel Inhibitor of Acetylcholinesterase, Butyrylcholinesterase, and BETA-Secretase 1: In Vitro and In Silico Studies. (PubMed, ACS Omega) - "BACE-1 inhibition assays have shown significant reduction at three micromolar. MD simulations demonstrated that silodosin promotes late stabilization of the AChE complex, but the simulations involving BuChE and BACE-1 revealed that the compound promotes system stabilization at early stages and has the structural requirements to inhibition."

Journal • Preclinical • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Pain • APP

Comparison of the First Dose and Efficacy of Alfuzosin, Tamsulosin and Silodosin in the Treatment of Benign Prostatic Hyperplasia. (PubMed, Arch Esp Urol) - "Silodosin provided the most rapid symptomatic improvement following initial administration, likely due to its high α1A-receptor selectivity. However, by the third month, all three agents showed similar clinical efficacy, supporting their use as viable treatment options tailored to patient-specific needs."

Clinical • Journal • Retrospective data • Benign Prostatic Hyperplasia

Sildosin as a Male Contraceptive Non Hormonal (clinicaltrials.gov) - P1 | N=200 | Not yet recruiting | Sponsor: Benha University

New P1 trial

Risk assessment of the top 60 drugs for drug-related sexual dysfunction: a disproportion analysis from the Food and Drug Administration adverse event reporting system. (PubMed, J Sex Med) - "We identified 34 drugs that may be related to SD, with a predominance in the nervous system. This finding suggests that clinicians should be aware of the risk of SD associated with these drugs."

Adverse events • Journal • Sexual Disorders

Does preoperative alpha-blocker use affect the results of flexible ureterorenoscopy? (PubMed, Actas Urol Esp (Engl Ed)) - "Alpha-blocker therapy during F-URS for upper urinary tract stones is associated with improved outcomes, including higher stone access rates, reduced complications, and increased stone-free rates. These findings suggest that alpha-blockers, particularly tamsulosin and silodosin, may enhance the efficacy and safety of F-URS."

Journal • Renal Calculi • Urolithiasis • Urology

Role of CT Scan in Prognosticating the Outcome of Medical Expulsive Therapy for Distal Ureteric Stone. (PubMed, Arch Esp Urol) - "MET is undoubtedly a treatment modality for lower ureteric stones of size 10 mm. On computed tomography (CT) scan, stone area can be used as an effective parameter, but stone density (HU) cannot determine MET success. Further studies that include more patients and an evaluation of stone composition are required."

Journal • Nephrology • Pain • Renal Calculi

Novel spectrophotometric approaches for analysis of solifenacin and silodosin in pharmaceutical preparations, human plasma, and environmental water samples: assessment of the methods' greenness and practicality. (PubMed, Anal Bioanal Chem) - "Method greenness and practicality were critically evaluated using the GAPI, AGREE, and the recently introduced CACI tool, all confirming the exceptional eco-friendliness and economic viability of the approaches. Full compliance with ICH Q2(R2) guidelines further affirms their validity for routine quality control and environmental monitoring."

Journal • Overactive Bladder

Prophylactic alpha-blockers for prevention of post-operative urinary retention after total mesorectal excision for cancer: A prospective multicenter study from the GRECCAR group (ESCP 2025) - "LOS was significantly shorter with Alfuzosin compared to both standard care(6 days [2-60] vs. 10 days [4-72],p<0.001) and Silodosin(8 days [5–40],p<0.001). Conclusion Prophylactic Alfuzosin significantly reduces post-operative urinary retention and re-catheterization rate after TME with a shorter LOS.This Alfuzosin protocol should be implemented in early rehabilitation programs in order to improve postoperative outcomes after rectal surgery."

Clinical • Benign Prostatic Hyperplasia • Colorectal Cancer • Oncology • Prostate Cancer • Rectal Cancer • Solid Tumor

A Phase III Clinical Study of H077 Sustained-Release Tablets Compared With Silodosin Capsules in the Treatment of Benign Prostatic Hyperplasia (clinicaltrials.gov) - P3 | N=728 | Not yet recruiting | Sponsor: Shanghai Huilun Pharmaceutical Co., Ltd.

Head-to-Head • New P3 trial • Benign Prostatic Hyperplasia

Genetic Modulation of Silodosin Exposure and Efficacy: The Role of CYP3A4, CYP3A5, and UGT2B7 Polymorphisms in Benign Prostatic Hyperplasia Management. (PubMed, J Pers Med) - " Genetic polymorphisms CYP3A4*22, CYP3A5*3, and UGT2B7 rs7439366 may modulate silodosin pharmacokinetics and efficacy parameters in BPH patients but not safety. Larger-scale studies are warranted to validate these initial findings."

Journal • Benign Prostatic Hyperplasia • ABCB1 • CYP3A4 • CYP3A5

Comparative efficacy and safety of silodosin and tadalafil combination or monotherapy for treating lower urinary tract symptoms due to benign prostatic obstruction: A systematic review and meta-analysis. (PubMed, Cent European J Urol) - "Silodosin and tadalafil are effective for treating LUTS in men due to BPO, especially when used in combination. However, with concerns about safety, tadalafil as monotherapy offers an advantage for patients with fertility desires due to its favorable side effect profile."

Journal • Monotherapy • Retrospective data • Review • Benign Prostatic Hyperplasia

Comparative Evaluation of Safety and Efficacy of Dapoxetine, Silodosin, and Citalopram in the Management of Premature Ejaculation (clinicaltrials.gov) - P4 | N=450 | Completed | Sponsor: Beni-Suef University

New P4 trial • Sexual Disorders

On-demand Silodosin 4mg vs Dapoxetine 60mg in Treatment of Primary Premature Ejaculation (clinicaltrials.gov) - P2/3 | N=95 | Completed | Sponsor: Benha University

New P2/3 trial • Sexual Disorders

Sustainable UV approaches backed by one step extraction procedure for quantifying the newly released mirabegron and silodosin mixture in urine. (PubMed, Sci Rep) - "Per the preceding, the applied approaches have been proven to be sustainable, delicate, and appropriate for quality control (QC) testing. Also, backing the applied approaches with the SALLE procedure enables precise monitoring of MIR and SIL in miscellaneous biological fluids with excellent recoveries, presenting an inventive approach for further bioanalytical applications."

Journal • Overactive Bladder

Medical Stone Expulsive Therapy for Acutely Obstructed Ureteric Calculi (clinicaltrials.gov) - P4 | N=240 | Completed | Sponsor: Getz Pharma | Recruiting ➔ Completed | Trial completion date: Dec 2025 ➔ Jun 2025

Trial completion • Trial completion date • Renal Calculi